BrAD-R13
| Clinical data | |
|---|---|
| Other names | BrADR13; Braegen-01; Braegen01 |
| Routes of administration | Oral[1] |
| Drug class | TrkB agonist |
BrAD-R13, also known as Braegen-01, is a small-molecule tropomyosin receptor kinase B (TrkB) agonist which is under development for the treatment of Alzheimer's disease, amyotrophic lateral sclerosis (ALS), depressive disorders, Parkinson's disease, and schizophrenia.[1][2][3][4] It is taken orally.[1] The drug is a derivative of 7,8-dihydroxyflavone (7,8-DHF; tropoflavin).[3][4] It was first described in the scientific literature by 2020.[3] BrAD-R13 is being developed by Braegen Pharmaceutical in China.[1][2] As of August 2025, it is in phase 1 clinical trials for Alzheimer's disease and the preclinical research stage of development for all other indications.[1][2] The exact chemical structure of BrAD-R13 does not yet appear to have been disclosed.[1]
See also
[edit]References
[edit]- ^ a b c d e f "BrAD R13". AdisInsight. 8 August 2025. Retrieved 24 January 2026.
- ^ a b c "Delving into the Latest Updates on BrAD-R13 with Synapse". Synapse. 20 December 2025. Retrieved 24 January 2026.
- ^ a b c Liu W, Wang X, O'Connor M, Wang G, Han F (2020). "Brain-Derived Neurotrophic Factor and Its Potential Therapeutic Role in Stroke Comorbidities". Neural Plasticity. 2020: 1969482. doi:10.1155/2020/1969482. PMC 7204205. PMID 32399020.
Recently, a derivative of 7,8-DHF, namely, BrAD-R13, was approved by the FDA for use in clinical trials for the treatment of mild to moderate AD.
{{cite journal}}: CS1 maint: article number as page number (link) - ^ a b Wang D, Lang ZC, Wei SN, Wang W, Zhang H (June 2024). "Targeting brain-derived neurotrophic factor in the treatment of neurodegenerative diseases: A review". Neuroprotection. 2 (2): 67–78. doi:10.1002/nep3.43. PMC 12486910. PMID 41383700.
BrAD‐R13, a derivative of 7,8‐ DHF, has been approved by the FDA for clinical trials in mild to moderate disease, with preclinical studies supporting its efficacy against AD and ALS.18,134–136 Recently, BrAD‐R13 has been registered for a Phase I trial in China (CTR20233658).
 | This drug article relating to the nervous system is a stub. You can help Wikipedia by adding missing information. |